KR20160056866A - COMPOSITION FOR PREVENTING, TREATING OR IMPROVING SKIN DISEASE, COMPRISING EXTRACT OF Cassia obtussifolia L. AND EXTRACT OF Hovenia ducis - Google Patents
COMPOSITION FOR PREVENTING, TREATING OR IMPROVING SKIN DISEASE, COMPRISING EXTRACT OF Cassia obtussifolia L. AND EXTRACT OF Hovenia ducis Download PDFInfo
- Publication number
- KR20160056866A KR20160056866A KR1020160057079A KR20160057079A KR20160056866A KR 20160056866 A KR20160056866 A KR 20160056866A KR 1020160057079 A KR1020160057079 A KR 1020160057079A KR 20160057079 A KR20160057079 A KR 20160057079A KR 20160056866 A KR20160056866 A KR 20160056866A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- present
- skin
- skin diseases
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 168
- 239000000203 mixture Substances 0.000 title claims abstract description 157
- 208000017520 skin disease Diseases 0.000 title claims abstract description 34
- 235000008586 Hovenia Nutrition 0.000 title description 4
- 241000405398 Hovenia Species 0.000 title description 4
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 25
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 23
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 18
- 206010020649 Hyperkeratosis Diseases 0.000 claims abstract description 13
- 208000001126 Keratosis Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 206010003645 Atopy Diseases 0.000 claims description 22
- 241000736199 Paeonia Species 0.000 claims description 16
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 15
- 239000009262 Puerariae Radix plant extract Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 12
- 230000006872 improvement Effects 0.000 claims description 12
- -1 n Species 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- 239000012676 herbal extract Substances 0.000 claims description 7
- 241001480043 Arthrodermataceae Species 0.000 claims description 6
- 240000002045 Guettarda speciosa Species 0.000 claims description 6
- 230000037304 dermatophytes Effects 0.000 claims description 6
- 229940069445 licorice extract Drugs 0.000 claims description 6
- 244000184734 Pyrus japonica Species 0.000 claims description 5
- 241001105098 Angelica keiskei Species 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims description 3
- 229940051810 licorice root extract Drugs 0.000 claims description 3
- 235000020725 licorice root extract Nutrition 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 235000006533 astragalus Nutrition 0.000 abstract description 13
- 208000000260 Warts Diseases 0.000 abstract description 10
- 201000010153 skin papilloma Diseases 0.000 abstract description 10
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 9
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 9
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 6
- 240000001810 Angelica gigas Species 0.000 abstract description 6
- 150000003431 steroids Chemical class 0.000 abstract description 5
- 235000008216 herbs Nutrition 0.000 abstract description 4
- 239000000419 plant extract Substances 0.000 abstract description 4
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract description 3
- 244000010000 Hovenia dulcis Species 0.000 abstract description 3
- 235000005338 Allium tuberosum Nutrition 0.000 abstract description 2
- 244000003377 Allium tuberosum Species 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract description 2
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 abstract description 2
- 241000132011 Atractylodes lancea Species 0.000 abstract description 2
- 241000555678 Citrus unshiu Species 0.000 abstract description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 2
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 2
- 241001474977 Palla Species 0.000 abstract description 2
- 206010037083 Prurigo Diseases 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 abstract description 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 244000277285 Cassia obtusifolia Species 0.000 abstract 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 abstract 1
- 230000037306 mature skin Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 29
- 238000012360 testing method Methods 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 18
- 239000008213 purified water Substances 0.000 description 14
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 12
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940010454 licorice Drugs 0.000 description 12
- 241000202807 Glycyrrhiza Species 0.000 description 11
- 210000004207 dermis Anatomy 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 208000003251 Pruritus Diseases 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 235000001602 Digitaria X umfolozi Nutrition 0.000 description 3
- 240000003176 Digitaria ciliaris Species 0.000 description 3
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 3
- 235000005476 Digitaria cruciata Nutrition 0.000 description 3
- 235000006830 Digitaria didactyla Nutrition 0.000 description 3
- 235000005804 Digitaria eriantha ssp. eriantha Nutrition 0.000 description 3
- 235000010823 Digitaria sanguinalis Nutrition 0.000 description 3
- 235000014716 Eleusine indica Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000029085 globe disease Diseases 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000092897 Angelica japonica Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 240000005109 Cryptomeria japonica Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000220324 Pyrus Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 241000219873 Vicia Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940117336 parsley extract Drugs 0.000 description 2
- 235000021017 pears Nutrition 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241001362614 Crassa Species 0.000 description 1
- 235000010071 Cucumis prophetarum Nutrition 0.000 description 1
- 244000024469 Cucumis prophetarum Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000003385 Diospyros ebenum Nutrition 0.000 description 1
- 241000792913 Ebenaceae Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 241000237955 Nassarius Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010041052 Sluggishness Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910000078 germane Inorganic materials 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 피부 질환을 예방, 치료 또는 개선하는 조성물에 관한 것으로, 구체적으로 아토피, 건선, 습진, 각화증, 양진 및 물사마귀 등의 난치성 피부 질환을 호전시킬 수 있는 새로운 한약 조성물에 관한 것이다.The present invention relates to a composition for preventing, treating or ameliorating skin diseases, and more particularly, to a new herbal composition capable of improving intractable skin diseases such as atopy, psoriasis, eczema, keratosis,
아토피성 피부염은 그 원인은 아직 정확히 밝혀져 있지 않으나, 일반적으로 환경과 음식 및 유전적 소인이 복합적으로 작용하여 발병하는 것으로 인식되고 있다. 그 외에 건조한 피부, 정상인보다 쉽게 가려움증을 느끼는 피부, 세균ㆍ바이러스ㆍ곰팡이 등에 의한 감염, 정서적 요인 등 여러 요인이 서로 복합적으로 관여하는 것으로 본다.Although the cause of atopic dermatitis has not been clarified yet, it is generally recognized that the environment, food, and genetic susceptibility act in a complex manner. Other factors include dry skin, skin that is more pruritic than normal skin, infections caused by bacteria, viruses, mold, and emotional factors.
아토피성 피부염은 가려움증이 가장 중요한 증상으로 대개 피부가 건조하며, 긁게 되면 가려움증이 발진(發疹)으로 이어지고 다시 가려움증을 일으키는 악순환을 하게 된다. 급성기에는 경계가 불확실한 홍반성 구진(紅斑性 丘疹)을 동반하고, 심하면 부종(浮腫), 진물, 찰상(擦傷), 가피(痂皮), 건조(乾燥), 태선화(苔癬化), 암화(暗化) 등을 보인다. 긁어서 상처가 생기면 포도상 구균에 의한 2차 감염이 있을 수 있고, 농포(膿疱)와 가피(痂皮)가 생긴다. 만성적으로 피부를 반복해서 긁기 때문에 태선화(苔癬化) 현상이 나타나고, 통증을 동반한 균열이 생기기도 하고, 반복적인 자극으로 색소가 침착되어 암화(暗化) 현상이 발생한다. 그러나, 이러한 병증에 그치지 않고 잦은 재발로 말미암은 의료비 부담 증가, 정상적인 학업 및 사회 활동의 제약, 우울증과 대인기피증, 자살 충동 등을 수반하는 경우가 많기 때문에 문제가 되고 있는 것이다. Atopic dermatitis is the most important symptom of itching, usually the skin is dry, and when it is scratched, itching leads to rash and itching again. The acute phase is accompanied by erythematous papules with uncertain boundaries and is accompanied by edema, dirt, scratches, crusts, dryness, lichenification, Darkening). Scratches can cause secondary infection by staphylococci, pustules and scabs. Chronic skin scratches repeatedly, resulting in the formation of lichen (lichenification) phenomenon, cracks accompanied by pain, and repetitive stimuli are deposited pigmentation occurs (darkening) phenomenon occurs. However, this problem is not only due to increased incidence of medical expenses due to frequent recurrence, restriction of normal academic and social activities, depression, gangrene, and suicidal impetus.
예전에는 '태열'이라 하여 어린 아이들에게 나타나는 것으로 알고 있었으나, 최근에는 성인이 되어 발병하는 경우가 증가하는 추세에 있다. 사회 활동이나 경제 활동을 할 수 없을 정도의 중증 성인 아토피 환자가 늘어나는 것은 국가적으로도 여러모로 손실이 크다. In the past, it was known as 'Taejil', which appeared to young children. Recently, however, there has been an increase in the number of adult cases. The increase in the number of serious atopic patients who can not do social activities or economic activities is also very large at the national level.
이러한 아토피성 피부염의 치료를 위해 양방에서는 스테로이드 제재 및 면역 억제제를 사용하고 있다. 그러나 스테로이드 제재의 경우 일시적으로 증상의 개선을 엿볼 수 있으나 지속적인 사용 후 중단 시에는 반동현상으로 인하여 아토피 증상이 더욱 심해지는 부작용이 많이 보고된다. 면역 억제제는 스테로이드를 대신할 수 있는 약물로 알려져 수입, 사용폭이 증가하고 있는데 최근 식약청은 일부 약물에 대해 그 발암 위험성 때문에 2세 이하의 아동이나 면역체계가 약화된 사람이 사용해서는 안된다는 입장을 표명하였고, 그 사용범위도 다른 치료제로 효능을 얻지 못한 경우나 아토피에 내성이 있는 경우의 2차 처방약으로 제한했으며, 사용기한도 단기간 또는 간헐적으로 쓰도록 지침을 내린 바 있다.Both steroids and immunosuppressants are used for the treatment of atopic dermatitis. However, in the case of steroid medication, the improvement of the symptoms can be seen temporarily. However, there are many side effects that the symptoms of atopy become worse due to the recoil phenomenon at the time of continuous use. Immunosuppressants are known to be substitutes for steroids and are increasing in terms of imports and use. Recently, the KFDA has expressed its position that some drugs should not be used by children under 2 years of age or by weakened immune systems due to the risk of cancer. And the scope of its use was restricted to the second prescription drugs that were not efficacious with other treatments or those resistant to atopy, and the guidelines were to be used shortly or intermittently.
최근에는 아토피 환자 중 상당수가 이러한 양방치료에 따른 부작용의 위험을 피하고자 한방치료와 천연 유래의 다양한 민간요법 등에 의존하는 경향이 늘어나고 있지만 이에 대한 과학적 근거가 충분히 제시되지 못하고 있는 실정이다.In recent years, many of atopic patients have been increasingly dependent on the treatment of herbal medicines and various folk remedies derived from natural sources in order to avoid the risk of side effects caused by such bilateral treatment, but the scientific basis for this is not sufficiently presented.
본 발명자는 이러한 문제를 해결하고자 예의 노력한 결과, 본 발명의 신규한 조성물이 아토피, 건선, 습진, 각화증, 양진 및 물사마귀 등과 같은 난치성 피부 질환의 개선에 효과적임을 알아내고, 이를 유소아와 난치성 성인 피부 질환자에 적용하여 그 효과를 검증함으로써, 본 발명을 완성하였다. As a result of intensive efforts to solve such problems, the present inventors have found that the novel composition of the present invention is effective for the treatment of intractable skin diseases such as atopy, psoriasis, eczema, keratosis, and water warts, The present invention has been completed by verifying the effect of the present invention.
따라서, 본 발명의 목적은 부작용없이 상기한 건선 등의 난치성 피부 질환을 호전시킬 수 있는 신규한 한약 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a novel herbal composition which can improve intractable skin diseases such as psoriasis without side effects.
상기 목적을 달성하기 위하여, 본 발명의 일 측면에 따르면, 결명자 추출물 및 지구병 추출물을 포함하는 피부 질환의 예방 또는 치료용 약학적 조성물을 제시할 수 있다. 본 발명의 일 구현 예에서 결명자 추출물 및 지구병 추출물은 건조 중량비로 1: 0.5 ~ 5의 비율로 포함될 수 있다. According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating skin diseases, which comprises Cercariae extract and globe extract. In one embodiment of the present invention, the Cassiae Extract and the Earth Disease Extract may be contained in a ratio of 1: 0.5 to 5 in a dry weight ratio.
또한, 본 발명의 조성물은 결명자 추출물 및 지구병 추출물과 함께 가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 1종 이상의 약재 추출물을 더 포함할 수 있다. In addition, the composition of the present invention may further comprise one or more kinds of medicinal herbs selected from the group consisting of Cereal extract and Earth disease extract together with a family extract, Huanggui extract, Angelica gigantosa extract, Puerariae radix extract, Extract. ≪ / RTI >
일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 가구자 추출물을 포함할 수 있다. 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 황기 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 당귀 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 갈근 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 백출 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 작약 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 진피 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 감초 추출물을 포함할 수 있다. 이들 첨가되는 약재의 중량은 건조 중량비로 결명자 추출물이 1 일때, 지구병 추출물은 0.5 내지 5이고, 그 외의 추출물 각각은 0.2 내지 5로 포함될 수 있다. In one embodiment, the compositions of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a Household Extract. In another embodiment, the composition of the present invention may comprise a Cassiae Extract, a Global Disease Extract, and a Hwanggi Extract. In another embodiment, the composition of the present invention may include a Cercy extract, a globe bottle extract, and a Guanyin guinea extract. In another embodiment, the composition of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a Puerariae Radix Extract. In another embodiment, the composition of the present invention may comprise a Cassiae Extract, an Earth Disease Extract, and a Parsley Extract. In another embodiment, the composition of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a Peony Extract. In another embodiment, the composition of the present invention may include a Cercy extract, a globe bottle extract and a dermis extract. In another embodiment, the composition of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a licorice extract. The weight of the medicinal materials to be added may be 0.5 to 5 in the case of the Cassiae Extract, 1 to 5 in the Earth Disease Extract, and 0.2 to 5 in the other extracts, in terms of the dry weight ratio.
한편, 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물, 가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물을 모두 포함할 수 있다. 상기 재료의 비율(건조 중량비)은 결명자 추출물이 1일 때, 지구병 추출물은 0.5 ~ 5의 비율이 되고, 그 외에 다른 약재는 각각 0.2 ~ 5의 비율이 되도록 조성할 수 있다. Meanwhile, in one embodiment, the composition of the present invention may include all of the following: Cryptomeria japonica extract, Earth jar extract, Household jar extract, Hwanggi extract, Angelica japonica extract, Puerariae Radix extract, Radix extract, Peony root extract, Dermatophyte extract and Licorice root extract. The ratio (dry weight ratio) of the above ingredients can be adjusted so that when the Cassiae Extract is 1, the ratio of the Earth's Disease Extract is 0.5 to 5, and the other medicines are 0.2 to 5.
일 구현 예에서 본 발명의 조성물은 건조 중량비로 결명자 추출물 : 지구병 추출물 : 가구자 추출물 : 황기 추출물 : 당귀 추출물 : 갈근 추출물 : 백출 추출물 : 작약 추출물 : 진피 추출물 : 감초 추출물이 1: 0.5 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5가 되도록 조성할 수 있다. In one embodiment, the composition of the present invention is used in a ratio of 1: 0.5 to 5: 1, preferably 1: 0.5 to 5: 1, to a dry weight ratio of Cassiae Extract: Earth Disease Extract: Furniture Extract: Huangzi Extract: Danggui Extract: Puerariae Radix Extract: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5.
본 발명의 약학 조성물이 적용 가능한 피부 질환은 아토피, 건선, 습진, 각화증, 양진 및 물사마귀으로 구성되는 군으로부터 선택되는 난치성 피부 질환이다. 상기 약학 조성물은 내복용으로 사용될 수 있다.The skin diseases to which the pharmaceutical composition of the present invention is applicable are intractable skin diseases selected from the group consisting of atopy, psoriasis, eczema, keratosis, ovulation and water warts. The pharmaceutical composition may be used for internal administration.
또한, 본 발명의 다른 일 측면에 따르면, 결명자 추출물 및 지구병 추출물을 포함하는 조성물을 포함하는 피부 질환 개선용 식품 조성물을 제시할 수 있다. 일 구현 예에서 상기 결명자 추출물 및 지구병 추출물은 건조 중량비로 1: 0.5 ~ 5의 비율로 포함될 수 있다. 또한, 본 발명의 식품 조성물은 가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 1종 이상의 약재 추출물을 더 포함할 수 있다. According to another aspect of the present invention, there is provided a food composition for improving skin diseases, which comprises a composition comprising a Cassiae japonica extract and a globe extract. In one embodiment, the Cassiae Extract and the Earth Disease Extract may be contained in a ratio of 1: 0.5 to 5 in a dry weight ratio. The food composition of the present invention may further comprise at least one herbal extract selected from the group consisting of a herbal extract, a Hwanggi extract, a Guanyin extract, a Puerariae radix extract, an extract, a peony extract, a dermis extract and a licorice extract .
아울러, 본 발명의 또 다른 일 측면에 따르면, 결명자 추출물 및 지구병 추출물을 포함하는 조성물을 포함하는 피부 질환 개선용 화장료 조성물을 제시할 수 있다. 일 구현 예에서 상기 결명자 추출물 및 지구병 추출물은 건조 중량비로 1: 0.5 ~ 5의 비율로 포함될 수 있다. 또한, 본 발명의 화장료 조성물은 가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 1종 이상의 약재 추출물을 더 포함할 수 있다.According to another aspect of the present invention, there is provided a cosmetic composition for improving skin diseases, which comprises a composition comprising a Cassiae japonica extract and a globe bottle extract. In one embodiment, the Cassiae Extract and the Earth Disease Extract may be contained in a ratio of 1: 0.5 to 5 in a dry weight ratio. In addition, the cosmetic composition of the present invention may further comprise one or more kinds of medicinal plant extracts selected from the group consisting of household extract, Hwanggi extract, Angelica gigantosa extract, Puerariae Radix extract, Paeoniae extract, Peony extract, Dermatophyte extract and Licorice extract .
본 발명의 조성물은 아토피, 건선, 습진, 각화증, 양진 및 물사마귀 등의 난치성 피부 질환을 효과적으로 호전시킬 수 있다. 본 발명의 조성물은 오래 전부터 식용으로 이용되어 왔던 식물 추출물들로 구성되어 있어 장기간 복용하여도 안전하며, 스테로이드제와 같은 부작용이 없으므로 피부 질환의 개선을 위해 유용하다. The composition of the present invention can effectively improve intractable skin diseases such as atopy, psoriasis, eczema, keratosis, ovarian hyperplasia and water warts. The composition of the present invention is composed of plant extracts that have been used for a long time and is safe for long-term use, and is useful for the improvement of skin diseases since there are no side effects such as steroids.
도 1의 (a) 및 (b)는 시험예 1에서 실시예 1의 조성물을 아토피 환자에게 적용하여 6개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 2의 (a) 및 (b)는 시험예 1에서 실시예 2의 조성물을 아토피 환자에게 적용하여 3개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 3의 (a) 및 (b)는 시험예 1에서 실시예 3의 조성물을 아토피 환자에게 적용하여 8개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 4의 (a) 및 (b)는 시험예 1에서 실시예 4의 조성물을 아토피 환자에게 적용하여 4개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 5의 (a) 및 (b)는 시험예 2에서 실시예 2의 조성물을 건선 환자에게 적용하여 6개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 6의 (a) 및 (b)는 시험예 2에서 실시예 4의 조성물을 건선 환자에게 적용하여 5개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 7의 (a) 및 (b)는 시험예 2에서 실시예 5의 조성물을 건선 환자에게 적용하여 6개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 8의 (a) 및 (b)는 시험예 2에서 실시예 6의 조성물을 건선 환자에게 적용하여 4개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 9의 (a) 및 (b)는 시험예 3에서 실시예 1의 조성물을 습진 환자에게 적용하여 8개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 10의 (a) 및 (b)는 시험예 3에서 실시예 7의 조성물을 습진 환자에게 적용하여 9개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 11의 (a) 및 (b)는 시험예 4에서 실시예 2의 조성물을 각화증 환자에게 적용하여 5개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 12의 (a) 및 (b)는 시험예 4에서 실시예 8의 조성물을 각화증 환자에게 적용하여 12개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 13의 (a) 및 (b)는 시험예 5에서 실시예 3의 조성물을 양진 환자에게 적용하여 5개월 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 14의 (a) 및 (b)는 시험예 5에서 실시예 9의 조성물을 양진 환자에게 적용하여 8주간 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.
도 15의 (a) 및 (b)는 시험예 6에서 실시예 10의 조성물을 물사마귀 환자에게 적용하여 4주간 경구 투여한 경과를 치료 전과 후로 나누어 보여주는 피부 사진이다.Figs. 1 (a) and 1 (b) are photographs of skin obtained by applying the composition of Example 1 to atopic patients in Test Example 1 and dividing the course of oral administration for 6 months before and after treatment.
FIGS. 2 (a) and 2 (b) are photographs of skin obtained by applying the composition of Example 2 to atopic patients in Test Example 1 and dividing the course of oral administration for 3 months before and after treatment.
FIGS. 3 (a) and 3 (b) are photographs showing the results obtained by applying the composition of Example 3 to atopic patients in Test Example 1 divided into 8 months before and after treatment.
FIGS. 4 (a) and 4 (b) are photographs of skin obtained by applying the composition of Example 4 to atopic patients in Test Example 1 and dividing the course of oral administration for 4 months before and after treatment.
Figures 5 (a) and 5 (b) are photographs of the skin of the composition of Example 2 in Test Example 2 divided between before and after treatment with 6 months oral administration applied to psoriasis patients.
FIGS. 6 (a) and 6 (b) are photographs showing the results obtained by applying the composition of Example 4 to patients suffering from psoriasis in Test Example 2 and dividing the time taken for oral administration for 5 months before and after treatment.
Figs. 7 (a) and 7 (b) are photographs of skin obtained by applying the composition of Example 5 to patients suffering from psoriasis in Test Example 2 and dividing the course of oral administration for 6 months before and after treatment.
8 (a) and 8 (b) are photographs showing the results obtained by applying the composition of Example 6 to patients suffering from psoriasis in Test Example 2 divided into 4 months before and after treatment.
9 (a) and 9 (b) are photographs of skin obtained by applying the composition of Example 1 to patients suffering from eczema in Test Example 3 and dividing the course of 8 months oral administration before and after treatment.
FIGS. 10 (a) and 10 (b) are photographs showing the results obtained by applying the composition of Example 7 to patients suffering from eczema in Test Example 3 and dividing the course of 9 months oral administration before and after treatment.
11 (a) and 11 (b) are photographs of skin obtained by applying the composition of Example 2 to a patient with keratosis in Test Example 4 and dividing the course of oral administration for 5 months before and after treatment.
FIGS. 12 (a) and 12 (b) are photographs showing the results obtained by applying the composition of Example 8 to a patient with keratosis in Test Example 4 and dividing the course of 12 months oral treatment before and after treatment.
13 (a) and 13 (b) are photographs showing the results of a 5-month oral administration of the composition of Example 3 applied to a positive patient in Test Example 5 before and after treatment.
14 (a) and 14 (b) are photographs showing the results of the oral administration of the composition of Example 9 to the patients of Positive Example for 8 weeks in Test Example 5 before and after the treatment.
15 (a) and 15 (b) are photographs showing the results of the oral administration of the composition of Example 10 applied to patients with water warts in Test Example 6 for four weeks before and after treatment.
이하, 본 명세서에 사용된 용어의 정의를 포함하여 본 발명을 실시하기 위한 구체적인 내용을 상세하게 설명한다.Hereinafter, specific details for carrying out the present invention will be described in detail, including definitions of terms used in this specification.
"아토피성 피부염(atopic dermatitis)"은 주로 유아기 혹은 소아기에 시작되는 만성적이고 재발성의 염증성 피부질환으로 소양증(가려움증)과 피부건조증, 특징적인 습진을 동반하는 피부염을 말한다. 초기에는 주로 가려움과 함께 수포, 구진, 홍반, 부종 등이 관찰되며 만성기에는 부종, 수포는 줄어드는 대신 피부 주름이 두드러지거나 피부가 두꺼워지는 태선화, 비늘, 색소침착 등을 보인다. 일반적으로 아토피 피부염과 습진은 동의어로 사용되고 있으나, 피부염은 모든 염증을 지칭하는 용어로, 엄밀한 정의로는 피부염이 습진보다 더 넓은 의미를 가진다."Atopic dermatitis" is a chronic, recurrent, inflammatory skin disease that usually starts in infancy or childhood. It refers to dermatitis accompanied by pruritus (itching), dry skin, and characteristic eczema. In the early stage, it usually causes itching, pus, papules, erythema and edema. In the chronic phase, swelling and blistering are noticeably reduced, but skin wrinkles become noticeable or skin becomes thickened, scales and pigmentation. In general, atopic dermatitis and eczema are used as synonyms, but dermatitis is a term referring to all inflammation. In strict definition, dermatitis has a wider meaning than eczema.
"건선(psoriasis)"은 은백색의 비늘로 덮여 있고, 경계가 뚜렷하며 크기가 다양한 붉은색의 구진이나 판을 이루는 발진이 전신의 피부에 반복적으로 발생하는 만성 염증성 피부병으로, 조직학적으로 표피의 각질세포의 증식과 진피의 염증을 특징으로 한다."Psoriasis" is a chronic inflammatory skin disease that is covered with silvery white scales, has a clear boundary, and has a red papule or plate rash that occurs repeatedly in the skin of the whole body. And inflammation of the dermis.
"습진(eczema)"은 공통적인 임상적, 조직학적 특징을 보이는 피부 질환군을 통칭하는 용어이다. 임상적으로 가려움증, 홍반, 비늘과 군집된 구진, 수포를 보이고, 조직학적으로는 표재성 피부염으로서 표피에는 해면화를 동반하며 진피에는 혈관 주변에 염증세포가 침윤된 염증성 피부반응을 보이는 피부질환군을 통칭한다."Eczema" is a generic term for a group of skin disorders that exhibit common clinical and histological features. Clinically, itching, erythema, scaly and clustered papules, blisters, histologically superficial dermatitis, with epidermis on the epidermis, and dermis on the skin with inflammatory skin reactions that infiltrate inflammatory cells around the blood vessels Collectively.
"각화증(keratosis)"이란 피부 표피의 최상층에 있는 각질층이 증식, 변화하여 까칠까칠해지거나 굳어지는 피부병"을 말한다. 표피의 각질이 증식할 뿐만 아니라, 때로는 털주머니의 각층이 표피의 각층보다도 심하게 증식하여 구진을 형성하는 수가 있다. 각질은 표피세포가 각화하여 생기는 것으로, 정상적인 각화과정에서는 각층에 세포핵을 발견할 수 없다. 그런데 각질증식의 경우에는 세포핵이 잘 염색되어 존재한다. The term "keratosis" refers to a dermatosis of the upper stratum of the epidermis that grows, changes or becomes harder or harder. "Not only does the keratinization of the epidermis proliferate, but sometimes the layers of the epidermis are more proliferated than the layers of the epidermis The keratin is formed by the keratinization of the epidermal cells, and in normal keratinization process, the nucleus can not be found in each layer. In case of keratinization, the nucleus is well stained.
"양진(prurigo)"은 가려움이 심한 신경성 피부질환으로서, 헤브라 양진이 대표적인 것이다. 이 밖에 15~30세인 사람에게 잘 발생하고 재빨리 쇠퇴하는 안창과 비슷한 급성양진을 비롯하여, 만성화하는 심상성 양진, 완고한 두드러기와 같은 것으로 보이는 결절성 양진, 임신 3~4개월에 사지의 바깥쪽에 나타나서 점차 중증으로 되는 임신성 양진 등이 있다. 임신성 양진은 경산부에 나타나는데, 출산과 동시에 치유된다. "Prurigo" is an itchy nervous skin disease, typical of Hebra. In addition, there is an acute inflammation similar to the inhalation that occurs well in people aged 15 to 30 and rapidly declines, a nodular enlargement that appears to be like a chronic urticaria, a stubborn urticaria, And pregnancy outbreaks. Pregnancy is manifested in midsection, which is cured at the same time as birth.
"물사마귀(wart)"는 면역력 저하로 인한 바이러스(HPV, human papillomavirus)감염을 원인으로 하며, 2~5 mm 정도의 작은 반구형으로 표면이 매끄럽고 색깔은 피부색 또는 분홍색으로서 중앙 부분에 움푹하게 들어간 모양을 가지며, 얼굴, 손등, 발등, 몸 부위, 항문, 성기 주위, 입술, 점막 또는 두피 등에 종종 발생된다."Water wart" is caused by a virus (HPV, human papillomavirus) infection caused by a decrease in immunity. It is a small hemispherical shape of about 2 to 5 mm and has a smooth surface. Color is skin color or pink, Such as the face, the back of the hand, the instep, the body, the anus, the perioral region, the lips, the mucous membrane or the scalp.
본 명세서에 사용되는 용어 "개선"은 본 발명을 내복한 경과로서 상기한 피부 질환의 완치는 물론 부분적 완치, 호전 및 경감을 포함한다.As used herein, the term "improvement" is an episode that underlies the present invention, as well as a partial cure, improvement, and alleviation of the aforementioned skin disease.
본 발명의 조성물을 제조하기 위해 사용한 한약재는 다음과 같다.The medicinal herbs used for preparing the composition of the present invention are as follows.
결명자(Cassia obtussifolia L.)의 다른 이름은 환동자(還瞳子)·양명(羊明)으로, 콩과 식물인 결명초의 여문 씨를 말려 사용하거나 미리 끓인 후 사용할 수 있으며, 간의 열을 내리고 맑게 하며 눈을 밝게 하고 이뇨제 작용이 있으며 변을 묽게 하여 대변이 잘 나오게 하는 작용을 한다. 상세하게는 간열(肝熱) 또는 풍열(風熱)로 인해 눈이 빨갛고 부으면서 아프거나 눈물이 많이 나올 때 사용하며, 또한 열로 인한 변비나 장이 건조하여 생긴 변비에 끓여 먹거나 가루로 만들어 먹어도 좋으며 혈압을 낮추거나 핏속의 콜레스테롤을 낮추는 작용을 하지만, 결명자에 들어 있는 안트라키논 화합물이 대장의 연동 운동을 세게 하여 과량으로 사용하는 경우 설사를 일으킬 수 있다는 것이 밝혀졌다.The other name of Cassia obtussifolia L. is Cucumis japonica and Yangmyeong, which can be used after drying or pre-boiling the lentil seeds of soybean plants, Lightening, diuretic action and thinning of the stomach, so that the stool works well. Specifically, it is used when the eyes are red due to hepatic fever or heat (wind heat), and it is used when sick or tears come out with a lot of boiling. It is also good to boil or eat in constipation caused by heat constipation or dryness, Lowering or lowering the cholesterol of the blood, but the anthraquinone compound in the cadaver has been found to cause diarrhea when the hyperlipidemic activity of the large intestine is increased and used.
지구병(헛개나무, Hovenia dulcis)은 열매, 뿌리, 가지, 잎에 포도당, 사과산, 칼슘을 비롯한 후랑구라닌, 호베닌, 호베느시드, 하벤산 등 인체에 유익한 성분들이 함유되어 있다. 헛개나무의 활성 화학물질이 숙취해소, 주독해소, 구취제거 및 간 해독 내지 변비에 탁월한 효과가 있다고 하며 생즙은 술독을 풀고 구역질을 멎게 한다고 하였다. 본 발명의 조성물의 제조에는 헛개나무의 열매, 가지, 뿌리, 잎이 각각 사용될 수도 있고, 이들 부위가 혼합 사용될 수도 있다.Globe ( Hovenia dulcis ) contains beneficial ingredients such as fruit, roots, branches and leaves in the body, including glucose, malic acid, calcium, furanguranin, hobenin, robein seed, and hasan. It is said that the active chemicals of Hovenia japonica have an excellent effect on eliminating hangover, eliminating toxins, removing bad breath and detoxifying liver and constipation. In the preparation of the composition of the present invention, fruits, branches, roots and leaves of Hovenia dulcis may be used respectively, or these parts may be mixed.
가구자(부추씨, semen of Allium tuberosum)는 구채자, 구채인, 기양초자, 초종유자라고도 한다. 구자의 전초인 부추는 정구지, 솔지라고도 하며 어혈을 풀어주는데 사용한다. 이 약은 냄새가 없고 약성은 맵고 달며 따듯하다. 무릎과 허리가 차고 아프며, 발기 부전과 설사 등을 치료한다. 소변이 잦고 근육과 뼈가 아픈 것을 다스린다. 또한, 혈압강화와 심장흥분 작용이 보고되었다. 본 발명의 조성물의 제조를 위해서는, 냄새 제거를 위해 가구자를 볶아서 간단히 한 번 끓인 후 사용하여도 좋다.Household (semen of Allium tuberosum ) is called a donor, a mushroom, a mushroom, and a citron. Leuco, the outpost, is also called a tongue, a sole, and is used to loosen the ebony. This medicine has no odor and the medicine is spicy and warm. Knee and back are cold and sore, treating erectile dysfunction and diarrhea. Urine is frequent and muscles and bones are sore. In addition, blood pressure enhancement and cardiac excitation were reported. For the preparation of the composition of the present invention, the household appliance may be roasted and simmered once to remove the odor.
황기(Astragalus membranaceus)는 콩과에 속하는 다년생 초본식물이다. 뿌리를 약재로 이용하는데 약효성분은 폴리산, 콜린(choline) 등이다. 동물실험에서 중추신경계통의 흥분작용과 이뇨작용이 현저하였고, 신염(腎炎)의 발생 및 단백뇨와 콜레스테롤혈증의 발생도 억제 내지 지연시켰으며, 혈압강하작용도 보고되었다. 쉽게 피로하고 힘이 약하며, 음성이 낮고 땀을 많이 흘리는 사람에게 예로부터 인삼 대용으로 많이 써왔다. 자궁하수·위하수·탈홍·자궁출혈에도 널리 이용되며, 체력을 항진시켜 주고 전신근육의 긴장도를 높여주는 효과도 있다. Astragalus membranaceus ) is a perennial herbaceous plant belonging to the soybean family. Root is used as a medicinal ingredient, and its active ingredients are polyacid, choline, and the like. In animal experiments, central nervous system excitement and diuretic effect were remarkable, and nephritis, proteinuria and cholesterolemia were suppressed or delayed, and hypotensive effect was also reported. It is easily fatigued, weak in strength, low in voice and has been used extensively as a substitute for ginseng in people who sweat a lot. It is widely used for uterine drainage, gastrointestinal tract, esophagus, and uterine bleeding. It also increases the physical strength and increases the tension of the whole body muscles.
당귀(Angelica gigas)는 피가 부족할 때 피를 생성해 주는 보혈작용(補血作用)이 잘 알려져 있다. 중국 당귀나 왜당귀의 뿌리로 만든 것은 보혈작용이 뛰어나며, 참당귀의 뿌리로 만든 약재는 보혈작용보다는 피를 원활히 순환하게 해주는 활혈작용(活血作用), 항암효과 및 혈압강하작용이 강하다. 약리학적으로 관상동맥의 혈류량을 촉진시키고, 적혈구 생성을 왕성하게 한다. Angelica gigas is well known for its blood-producing (blood-clotting) effects when blood is scarce. Chinese roots of Angelica or Angelica gigas are excellent in blood circulation, and medicinal materials made from root of Angelica angustifolia have strong antitumor activity, anticancer effect and blood pressure lowering effect which cause blood to circulate more smoothly than blood. Pharmacologically, it promotes the blood flow of the coronary arteries and makes the production of red blood cells active.
갈근(Pueraria thunbergiana)은 계재(鷄齋), 녹두(豆), 건갈(乾葛), 감갈(甘葛), 분갈(粉葛), 황근(黃斤) 등의 이명을 가지고 있으며, 땀을 내고 열을 내려 고열, 두통을 치료하고 갈증을 멎게 한다. 소화불량, 두통, 빈혈, 이질, 복통, 술독, 감기, 구토, 부인들의 하혈 치료에 쓰이고 소화를 돕는다. 생뿌리를 짓찧어 즙을 내어 마시기도 한다. Pueraria thunbergiana has tinnitus such as mulberry, mung bean, dry giganta, ganggal, bangal, and hwangryeong, and sweat It feels high fever, cures headaches and stops thirst. Indigestion, headache, anemia, dysentery, abdominal pain, digestion, cold, vomiting, is used to treat hemorrhoids in women and helps digestion. It blooms raw roots and sucks and drinks.
백출은 국화과의 삽주(Atractylodes japonica Koidzumi) 또는 백출(Atractylodes macrocephala Koidzumi)의 뿌리줄기 또는 주피를 제거하여 말린 약재로, 비위(脾胃)의 기능이 허약해서 소식, 권태감이 생기고 얼굴빛이 황색이며 대변을 묽게 보거나 설사에 좋으며 수분이 정체되어 전신이 붓고 소화가 안 될때 수분 배설을 돕는다. 비(脾)에 수(水)와 습(濕)이 쌓여 담음(痰飮)으로 인한 가슴 뜀, 기침, 맑은 가래등에도 쓰며 비기(脾氣) 허약으로 피부에 땀이 저절로 날때, 임신 구토에도 사용한다. 위장 장애가 있는 감기, 사지동통에도 쓴다.It is a dried medicinal substance by removing the roots or juniors of Atractylodes japonica Koidzumi or Atractylodes macrocephala Koidzumi. It is weak in the function of the stomach, resulting in a feeling of malaise, yellowish facial color, It is good for diarrhea, and the water is stagnant and helps to excrete the water when the whole body is swollen and not digested. It is also used for boobs, coughs, and clear phlegm due to accumulation of water and wetness in the spleen. It is also used for the vomiting of pregnancy when sweating on the skin spontaneously due to weakness. do. It is also used for colds and limb pain with gastrointestinal disorders.
작약(Paeonia lactiflora Pallas)은 쌍떡잎식물 작약과 작약 속의 여러해 살이 풀로 모란과의 함박꽃 뿌리를 말린 것을 말하며, 높이는 1m 내외이고 꽃 색깔에 따라 백작약과 적작약으로 나뉜다. 이러한 작약에 함유되어 있는 배당체 성분은 중추신경계를 억제해 진통 효과를 주며, 음식을 잘못 섭취해 발생할 수 있는 소화불량, 복통, 설사, 복명을 치료하는데 탁월한 효과를 보일 뿐만 아니라 위장염이나 위장의 경련성 동통을 완화하는 데에도 도움을 준다. Paeonia lactiflora Pallas) is a perennial herbaceous perennial plant of peonies and peonies, and is dried to the roots of peonies. It is about 1m in height, and is divided into black and white depending on the flower color. The glycoside components contained in these peonies inhibit the central nervous system and give analgesic effect. Not only does it exert an excellent effect in treating digestive problems, abdominal pain, diarrhea, and double blindness which may be caused by misapplication, but also gastrointestinal It also helps to alleviate.
진피는 우리나라에서는 운향과의 귤(Citrus unshiu) 또는 동속 근연식물의 성숙한 과피를 말한다. 진피는 기가 뭉친 것을 풀어주고 비장의 기능을 강화하여 복부 창만, 트림, 구토, 메스꺼움, 소화불량, 헛배가 부르고 나른한 증상, 대변이 묽은 증상을 치료한다. 해수, 가래를 없애주며 이뇨작용을 한다. 정유 성분이 소화기 자극, 소화촉진, 거담, 항궤양, 항 위액분비 작용을 하는 것으로 보고되었다. The dermis is the mature peri of the citrus unshiu or relative plants in Korea. The dermis cleanses the gums and strengthens the function of the spleen, treating only the abdominal cavity, trimming, vomiting, nausea, indigestion, sluggishness, lingering symptoms, and thin stools. Seawater, sputum and diuretic action. Essential oil components have been reported to exert digestive stimulation, digestive stimulation, germane, anti-ulcer, and antidiarrheal secretion.
감초(Glycyrrhiza uralensis)는 약용식물로서, 중국 동북부와 시베리아, 몽골 등지에 분포하는데, 뿌리는 단맛이 나서 감미료, 한약재로 사용한다. 약의 독을 중화시키고, 소화흡수를 증진시키는 효과가 있다.Licorice ( Glycyrrhiza uralensis ) is a medicinal plant, distributed in northeastern China, Siberia and Mongolia, and its roots are used as sweeteners and herbal medicines. It has the effect of neutralizing poison of medicine and promoting digestion and absorption.
본 발명의 조성물은 결명자 추출물 및 지구병 추출물을 포함하여 제조되며, 본 발명의 발명자들은 본 발명에 따른 조성물이 아토피, 건선, 습진, 각화증, 양진 및 물사마귀 등의 난치성 피부 질환을 개선하고 치료하는 데에 우수한 효과를 갖는 것을 발견하여 본 발명에 이르게 되었다. 본 발명의 일 구현 예에서 상기 결명자 추출물 및 지구병 추출물은 건조 중량비로 1: 0.5 ~ 5의 비율로 포함될 수 있다. The composition of the present invention is prepared including a Cercy extract and a globe bottle extract. The inventors of the present invention have found that the composition according to the present invention is useful for improving and treating intractable skin diseases such as atopy, psoriasis, eczema, keratosis, And has reached the present invention. In one embodiment of the present invention, the Cassiae Extract and the Earth Disease Extract may be contained in a ratio of 1: 0.5 to 5 in a dry weight ratio.
또한, 본 발명의 조성물은 결명자 추출물 및 지구병 추출물과 함께 가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 1종 이상의 약재 추출물을 더 포함하도록 조성할 수 있다.In addition, the composition of the present invention may further comprise one or more kinds of medicinal herbs selected from the group consisting of Cereal extract and Earth disease extract together with a family extract, Huanggui extract, Angelica gigantosa extract, Puerariae radix extract, The composition may further comprise an extract.
일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 가구자 추출물을 포함할 수 있다. 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 황기 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 당귀 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 갈근 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 백출 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 작약 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 진피 추출물을 포함할 수 있다. 또 다른 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물 및 감초 추출물을 포함할 수 있다.In one embodiment, the compositions of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a Household Extract. In another embodiment, the composition of the present invention may comprise a Cassiae Extract, a Global Disease Extract, and a Hwanggi Extract. In another embodiment, the composition of the present invention may include a Cercy extract, a globe bottle extract, and a Guanyin guinea extract. In another embodiment, the composition of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a Puerariae Radix Extract. In another embodiment, the composition of the present invention may comprise a Cassiae Extract, an Earth Disease Extract, and a Parsley Extract. In another embodiment, the composition of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a Peony Extract. In another embodiment, the composition of the present invention may include a Cercy extract, a globe bottle extract and a dermis extract. In another embodiment, the composition of the present invention may include a Cassiae Extract, an Earth Disease Extract, and a licorice extract.
단, 본 발명의 조성물은 상기와 같은 조합으로 한정할 것은 아니고, 결명자 추출물 및 지구병 추출물을 필수 성분으로 포함하되, 가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 약재 추출물 2종 이상을 조합하여 더 포함하도록 조성할 수 있다. 일 구현 예에서 본 발명의 조성물은 결명자 추출물, 지구병 추출물, 가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물을 모두 포함할 수 있다.However, the composition of the present invention is not limited to the above-mentioned combination, and it is not limited to the above-mentioned combination, but it is preferable that the composition of the present invention includes the Cassiae Extract and the Earth Disease Extract as essential components, Extracts and licorice extracts of the present invention. In one embodiment, the composition of the present invention may include all of the following: Cryptomeria japonica Extract, Earth Disease Extract, Household Extract, Hwanggi Extract, Angelica keiskei Radix Extract, Puerariae Radix Extract, Leaf Extract, Peony Extract, Dermatophyte Extract and Licorice Extract.
본 발명의 조성물에서 결명자 추출물 및 지구병 추출물에 추가로 첨가되는 약재 추출물의 중량은 건조 중량비로 결명자가 1 일때 각각 0.2 내지 5로 포함될 수 있다. In the composition of the present invention, the weight of the Cassiae Extract and the Drug Extract added to the Disease Extract may be 0.2 to 5, respectively, when the Cassiae is 1 at a dry weight ratio.
일 구현예에서 본 발명의 조성물은 건조 중량비로 결명자 추출물 : 지구병 추출물 : 가구자 추출물 : 황기 추출물 : 당귀 추출물 : 갈근 추출물 : 백출 추출물 : 작약 추출물 : 진피 추출물 : 감초 추출물이 1: 0.5 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5: 0.2 ~ 5가 되도록 조성할 수 있다.In one embodiment, the composition of the present invention is used in a ratio of 1: 0.5 to 5: 1, preferably 1: 0.5 to 5: 1, to a dry weight ratio of Cassiae Extract: Earth Disease Extract: Furniture Extract: Huangzi Extract: Danggui Extract: Puerariae Radix Extract: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5: 0.2 to 5.
아울러, 본 발명의 조성물은 상기한 약재들 외에도 맛이나 풍미 등을 위해 당업계에서 통상적으로 첨가하는 약재들도 추가적으로 포함할 수 있다. In addition, the composition of the present invention may further include medicinal materials conventionally added in the art for taste, flavor, etc., in addition to the medicaments described above.
또한, 본 발명의 조성물은 내복용이나 외용으로 사용하기 위하여 약재를 추출하여 제조되는 추출물들을 포함할 수 있다. 일 구현 예에서, 본 발명의 조성물은 약재들 각각의 추출물을 혼합하여 포함할 수 있고, 다른 구현 예에서는 혼합된 약재로부터 얻어진 추출물을 포함할 수 있다.In addition, the composition of the present invention may include extracts prepared by extracting a pharmacological agent for use as an internal or external use. In one embodiment, the composition of the present invention may comprise a mixture of the extracts of each of the medicaments, and in other embodiments may comprise an extract obtained from the mixed medicament.
이때 약재의 추출물은 통상의 추출방법을 이용하여 제조될 수 있다. 즉 추출 용매를 상기 약재에 가하여 고온에서 저압 또는 고압 조건에서 추출하는 방법을 사용할 수 있다. 추출 용매로서는, 예를 들어 물, 탄소수 1 내지 4의 저급 알콜 또는 이들을 혼합한 혼합 용매를 사용할 수 있다. 용매의 사용량에는 특별한 제한이 있는 것은 아니나, 추출 효율, 조성물의 효능 또는 경제성 등을 고려할 때 용매의 양은 추출 대상 약재의 건조 중량 대비 1 내지 50배 정도 사용할 수 있다.At this time, the extract of the medicinal material can be produced by a conventional extraction method. That is, a method may be used in which an extraction solvent is added to the above-mentioned medicinal material and extraction is carried out at a high temperature under a low pressure or a high pressure. As the extraction solvent, for example, water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent obtained by mixing them can be used. There is no particular limitation on the amount of the solvent to be used, but the amount of the solvent may be about 1 to 50 times the dry weight of the drug substance to be extracted, considering the extraction efficiency, the efficacy or economical efficiency of the composition, and the like.
일 구현 예에서, 본 발명의 조성물은 각각의 약재(이때, 각 약재는 추출 전 분쇄기로 분쇄하거나 잘게 자른 것을 이용할 수 있다)를 적정한 용매를 이용하여 추출한 후 이를 혼합하여 제조될 수도 있으며, 혼합 약재를 함께 추출하여 추출 당시부터 각 추출물이 혼합된 형태로 제조할 수 있다.In one embodiment, the composition of the present invention may be prepared by extracting each medicament (wherein each medicament may be ground or chopped with a grinder prior to extraction) using a suitable solvent and mixing them, Can be extracted together, and the extracts can be prepared in a mixed form from the time of extraction.
한편, 상기 추출물을 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조한 후 이러한 분말을 사용할 수도 있음은 물론이다.Needless to say, it is also possible to use the powder after the powder is prepared by an additional process such as vacuum distillation, freeze-drying, or spray drying.
본 발명의 조성물의 구체적인 제조방법으로서 하기와 같은 방법이 있다.A specific method for producing the composition of the present invention is as follows.
결명자 및 지구병 외에 가구자, 황기, 당귀, 갈근, 백출, 작약, 진피 및 감초로 구성되는 군으로부터 선택되는 1종 이상의 약재를 택하여 약재의 총 건조 중량에 대하여 물을 1 내지 50배의 중량만큼 첨가하여 열수 추출한다. 상기 추출 조건은 50~130℃에서 2 내지 10시간, 바람직하게는 80~130℃에서 3 내지 6시간 추출할 수 있으나, 이로 제한되는 것은 아니다. 본 발명의 일 실시예에서는 1회 전탕에서 추출하는 양은 95,000mL 정도의 대용량으로 추출하여 내용물의 성분변화를 줄이고자 했다.In addition to the severer and the earth disease, one or more kinds of medicinal materials selected from the group consisting of furniture, hwanggi, angelica, crabgrass, peony, peony, dermis and licorice are selected and water is added in an amount of 1 to 50 times To extract hot water. The extraction conditions may be extracted at 50 to 130 ° C for 2 to 10 hours, preferably 80 to 130 ° C for 3 to 6 hours, but are not limited thereto. In one embodiment of the present invention, the amount extracted from a single bath was extracted at a large capacity of about 95,000 mL to reduce the compositional change of the contents.
상기와 같이 제조된 본 발명의 조성물은 내복을 위하여 포장될 수 있으며, 이 경우 1회당 20 내지 150 ml의 용량으로 포장할 수 있다. 내복의 경우, 1일 3회 음용할 수 있으나, 연령, 증상의 경중이나 증상의 개선도를 고려하여 용량이나 내복 횟수를 적절히 조절할 수 있다. 또한, 유아의 섭취 시 거부감을 줄이기 위하여, 본 발명의 조성물은 올리고당을 더 포함할 수 있다. The composition of the present invention prepared as described above may be packaged for underwear, and may be packed in a capacity of 20 to 150 ml per one time. In the case of underwear, it can be drunk three times a day, but the capacity and the number of underwear can be adjusted appropriately considering the age, the severity of the symptoms and the improvement of the symptoms. In addition, in order to reduce the feeling of rejection upon ingestion of infants, the composition of the present invention may further include oligosaccharides.
한편, 본 발명의 일 측면은 상기한 조성물을 피부 질환을 예방 또는 치료하기 위한 약학적 조성물로 이용될 수 있다. Meanwhile, one aspect of the present invention can be used as a pharmaceutical composition for preventing or treating skin diseases.
여기서, 본 발명의 약학 조성물은 통상의 방법에 따른 적절한 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 본 발명의 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 타가토스(Tagatose), 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. Here, the pharmaceutical composition of the present invention may further comprise an appropriate carrier, excipient or diluent according to a conventional method. Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include Tagatose, Lactose, Dextrose, Sucrose, Sorbitol, Mannitol, Xylitol, Erythritol, Maltitol, Starch, Acacia Rubber, Alginate, Gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
또한, 본 발명에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상세하게는, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 본 발명의 약학 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스 (sucrose), 락토오스 (lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.In addition, the pharmaceutical composition according to the present invention can be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like, oral preparation, suppository or sterilized injection solution, Can be used. More specifically, when formulating the composition, it can be prepared using a diluent or an excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like. Such solid preparations can be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, syrups and the like, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used diluents such as water and liquid paraffin . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
또 다른 측면에서, 본 발명의 조성물은 피부 질환의 개선을 위한 식품 조성물로 다양하게 이용될 수 있다. 본 발명의 조성물을 유효성분으로 포함하는 식품 조성물은 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 분말, 과립, 정제, 캡슐, 과자, 떡, 빵 등의 형태로 제조될 수 있다. 본 발명의 식품 조성물은 독성 및 부작용이 거의 없는 식물추출물로 구성된 것이므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다.In another aspect, the composition of the present invention can be used in various ways as a food composition for the improvement of skin diseases. The food composition containing the composition of the present invention as an active ingredient may be prepared in the form of various foods such as beverage, gum, tea, vitamin complex, powder, granule, tablet, capsule, . Since the food composition of the present invention is composed of a plant extract having little toxicity and side effects, it can be safely used for prolonged use even for prophylactic purposes.
본 발명의 조성물이 식품 조성물에 포함될 때 그 양은 전체 중량의 0.1 내지 50%의 비율로 첨가할 수 있다.When the composition of the present invention is contained in the food composition, the amount thereof may be added in a proportion of 0.1 to 50% of the total weight.
여기서, 상기 식품 조성물이 음료 형태로 제조되는 경우 지시된 비율로 상기 식품 조성물을 함유하는 것 외에 특별한 제한점은 없으며 통상의 음료와 같이 여러가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 즉, 천연 탄수화물로서 포도당 등의 모노사카라이드, 과당 등의 디사카라이드, 슈크로스 등의 및 폴리사카라이드, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜 등을 포함할 수 있다. 상기 향미제로서는 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등) 등을 들 수 있다. Here, when the food composition is prepared in a beverage form, there are no particular limitations other than those containing the food composition at the indicated ratios and may contain various flavors or natural carbohydrates such as ordinary beverages as an additional ingredient. That is, natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, sucrose and the like and sugar sugars such as polysaccharide, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol can do. Examples of the above-mentioned flavors include natural flavors (such as tau martin and stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavors (for example, saccharine and aspartame).
그 외 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition, the food composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants, pectic acid and its salts, alginic acid and its salts, , a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated drink, and the like.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.1 내지 약 50 중량부의 범위에서 선택되는 것이 일반적이다.These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0.1 to about 50 parts by weight per 100 parts by weight of the composition of the present invention.
또 다른 측면에서, 본 발명의 조성물은 피부 질환의 개선을 위한 화장료 조성물에도 이용될 수 있다. 본 발명의 조성물을 유효성분으로 포함하는 화장료 조성물은 화장수, 영양로션, 영양에센스, 마사지 크림, 미용목욕물첨가제, 바디로션, 바디밀크, 배스오일, 베이비오일, 베이비파우더, 샤워겔, 샤워크림, 선스크린로션, 선스크린크림, 선탠크림, 스킨로션, 스킨크림, 자외선차단용 화장품, 크렌징밀크, 탈모제{화장용}, 페이스 및 바디로션, 페이스 및 바디크림, 피부미백크림, 핸드로션, 헤어로션, 화장용크림, 쟈스민오일, 목욕비누, 물비누, 미용비누, 샴푸, 손세정제(핸드클리너), 약용비누{비의료용}, 크림비누, 페이셜워시, 헤어린스, 화장비누, 치아미백용 겔, 치약 등의 형태로 제조될 수 있다. 이를 위해 본 발명의 조성물은 화장료 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 더 포함할 수 있다.In another aspect, the composition of the present invention can be used in cosmetic compositions for improving skin diseases. The cosmetic composition comprising the composition of the present invention as an active ingredient can be used as a skin lotion, a nutritional lotion, a nutrition essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, Skin lotions, skin creams, sunscreen cosmetics, cleansing milks, hair removal products, cosmetics, face and body lotions, face and body creams, skin whitening creams, hand lotions, hair lotions, (Non-medical use), cream soap, facial wash, hair rinse, make-up soap, tooth whitening gel, toothpaste, etc. . ≪ / RTI > To this end, the compositions of the present invention may further comprise suitable carriers, excipients or diluents conventionally used in the preparation of cosmetic compositions.
본 발명의 화장료 조성물 내에 더 추가될 수 있는 담체, 부형제 또는 희석제로는 정제수, 오일, 왁스, 지방산, 지방산 알콜, 지방산 에스테르, 계면활성제, 흡습제(humectant), 증점제, 항산화제, 점도 안정화제, 킬레이팅제, 완충제, 저급 알콜 등이 포함되지만, 이에 제한되는 것은 아니다. 또한, 필요에 따라 미백제, 보습제, 비타민, 자외선 차단제, 향수, 염료, 항생제, 항박테리아제, 항진균제를 포함할 수 있다. The carrier, excipient or diluent which may further be added to the cosmetic composition of the present invention include purified water, oil, wax, fatty acid, fatty acid alcohol, fatty acid ester, surfactant, humectant, thickener, antioxidant, Buffers, lower alcohols, and the like, but are not limited thereto. Further, if necessary, it may contain a whitening agent, a moisturizing agent, a vitamin, an ultraviolet screening agent, a perfume, a dye, an antibiotic, an antibacterial agent, and an antifungal agent.
상기 오일로서는 수소화 식물성유, 피마자유, 면실유, 올리브유, 야자인유, 호호바유, 아보카도유가 이용될 수 있으며, 왁스로는 밀랍, 경랍, 카르나우바, 칸델릴라, 몬탄, 세레신, 액체 파라핀, 라놀린이 이용될 수 있다.As the oil, hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm oil, jojoba oil and avocado oil may be used. Examples of the wax include wax, wax, carnauba, candelilla, montan, ceresin, liquid paraffin, Can be used.
지방산으로는 스테아르산, 리놀레산, 리놀렌산, 올레산이 이용될 수 있고, 지방산 알콜로는 세틸 알콜, 옥틸 도데칸올, 올레일 알콜, 판텐올, 라놀린 알콜, 스테아릴 알콜, 헥사데칸올이 이용될 수 있으며 지방산 에스테르로는 이소프로필 미리스테이트, 이소프로필 팔미테이트, 부틸 스테아레이트가 이용될 수 있다. 계면 활성제로는 당업계에 알려진 양이온 계면활성제, 음이온 계면활성제 및 비이온성 계면활성제가 사용가능하며 가능한 한 천연물 유래의 계면활성제가 바람직하다. As the fatty acid, stearic acid, linoleic acid, linolenic acid and oleic acid may be used. As the fatty acid alcohol, cetyl alcohol, octyldodecanol, oleyl alcohol, panthenol, lanolin alcohol, stearyl alcohol and hexadecanol may be used As fatty acid esters, isopropyl myristate, isopropyl palmitate, and butyl stearate may be used. As the surfactant, a cationic surfactant, an anionic surfactant and a nonionic surfactant known in the art can be used, and a surfactant derived from a natural material is preferably used.
그 외에도 화장품 분야에서 널리 알려진 흡습제, 증점제, 항산화제 등을 포함할 수 있으며, 이들의 종류와 양은 당업계에 공지된 바에 따른다. In addition, it may contain a hygroscopic agent, a thickening agent, an antioxidant and the like widely known in the field of cosmetics, and the kind and amount thereof are well known in the art.
실시예Example
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention, and it is to be understood by those skilled in the art that the present invention is not limited thereto It will be obvious.
실시예 1: 조성물의 제조Example 1: Preparation of composition
생약재로 시판되는 결명자 2kg과 지구병(헛개나무 열매와 가지) 1kg에 정제수 20L를 가하여 100℃에서 6시간 추출하여 추출물을 제조하였다.20kg of purified water was added to 2kg of the commercially available herbaceous herb and 1kg of the globe (Hovenia fruit and branch), and the extract was extracted at 100 ° C for 6 hours.
실시예 2: 조성물의 제조Example 2: Preparation of composition
생약재로 시판되는 결명자 1kg과 지구병(헛개나무 열매와 가지) 2.5kg, 갈근 1kg 및 감초 300g에 정제수 30L를 가하여 120℃에서 3시간 추출하여 추출물을 제조하였다.30 kg of purified water was added to 1 kg of commercially available herbaceous herb, 2.5 kg of globe disease (hovenous fruit and eggplant), 1 kg of Puerariae crassa and 300 g of licorice, and extracted at 120 ° C for 3 hours to prepare an extract.
실시예 3: 조성물의 제조Example 3: Preparation of composition
생약재로 시판되는 결명자 1kg과 지구병(헛개나무 열매와 가지) 3kg, 백출 2kg, 백작약 2kg 및 감초 600g에 정제수 40L를 가하여 100℃에서 6시간 추출하여 추출물을 제조하였다.Extracts were prepared by adding 40 L of purified water to 1 kg of commercially available herbivorous herbaceous herb, 3 kg of globe disease (hovenous fruit and branches), 2 kg of pears, 2 kg of pears, 600 g of licorice and 6 g of purified water.
실시예 4: 조성물의 제조Example 4: Preparation of composition
생약재로 시판되는 결명자 1kg과 지구병(헛개나무 열매와 가지) 4kg, 당귀 1kg, 백작약 2kg, 진피 1kg, 가구자 500g 및 감초 500g에 정제수 40L를 가하여 110℃에서 4시간 추출하여 추출물을 제조하였다.Extracts were prepared by adding 40 L of purified water to 1 kg of commercially available herbaceous herb, 4 kg of Angelica japonica, 4 kg of Angelica keiskei, 1 kg of Angelica gigas, 2 kg of vetch, 1 kg of dermis, 500 g of caramel and 500 g of licorice.
실시예 5: 조성물의 제조Example 5: Preparation of composition
생약재로 시판되는 결명자 1kg과 지구병(헛개나무 열매와 가지) 4kg, 당귀 1kg, 백작약 2kg, 진피 500g 및 감초 500g에 정제수 40L를 가하여 110℃에서 4시간 추출하여 추출물을 제조하였다.Extracts were prepared by adding 40 L of purified water to 1 kg of a commercially available herbaceous herb, 4 kg of globular disease (Hovenia dulcifera and branches), 1 kg of Angelica gigas, 1 kg of dill, 500 g of dermis and 500 g of licorice.
실시예 6: 조성물의 제조Example 6: Preparation of composition
생약재로 시판되는 결명자 2kg과 지구병(헛개나무 열매와 가지) 0.5kg, 황기 1kg, 가구자 2kg, 갈근 2kg 및 감초 600g에 정제수 30L를 가하여 100℃에서 6시간 추출하여 추출물을 제조하였다.Extracts were prepared by adding 30 L of purified water to 2 kg of commercially available herbivorous herbivorous products, 0.5 kg of gloves (hovenous fruit and branches), 1 kg of Hwanggi, 2 kg of crabgrass, 2 kg of crabgrass and 600 g of licorice and then extracted at 100 ° C for 6 hours.
실시예 7: 조성물의 제조Example 7: Preparation of composition
생약재로 시판되는 결명자 2kg과 지구병(헛개나무 열매와 가지) 5kg, 백작약 2kg, 진피 1kg 및 감초 2kg에 정제수 60L를 가하여 120℃에서 3시간 추출하여 추출물을 제조하였다.60kg of purified water was added to 2kg of the commercially available herbaceous herb, 5kg of globe disease, 2kg of vetch, 1kg of dandruff and 2kg of licorice, and extracted at 120 DEG C for 3 hours to prepare an extract.
실시예 8: 조성물의 제조Example 8: Preparation of composition
생약재로 시판되는 결명자 1kg과 지구병(헛개나무 열매와 가지) 1.5kg, 백출 3kg, 진피 1kg, 가구자 2kg, 갈근 1kg 및 감초 500g에 정제수 40L를 가하여 100℃에서 6시간 추출하여 추출물을 제조하였다.Extracts were prepared by adding 40 L of purified water to 1 kg of commercially available herbivorous herbivore, 1.5 kg of dwarf bark, 3 kg of dwarf, 1 kg of dandruff, 2 kg of garlic, 1 kg of Puerariae and 500 g of licorice, .
실시예 9: 조성물의 제조Example 9: Preparation of composition
생약재로 시판되는 결명자 3kg과 지구병(헛개나무 열매와 가지) 3kg, 당귀 2kg, 황기 2kg, 갈근 1kg 및 감초 1kg에 정제수 60L를 가하여 120℃에서 3시간 추출하여 추출물을 제조하였다.The extract was prepared by adding 60 L of purified water to 3 kg of the commercially available herbaceous herbaceous herb, 3 kg of the globe, 2 kg of Angelica gigas, 2 kg of Hwanggi, 1 kg of Puerariae, and 1 kg of licorice and then extracted at 120 ° C for 3 hours.
실시예 10: 조성물의 제조Example 10: Preparation of composition
생약재로 시판되는 결명자 1kg과 지구병(헛개나무 열매와 가지) 5kg, 황기 1kg, 백출 2kg, 진피 1.5kg 및 감초 500g에 정제수 60L를 가하여 100℃에서 4시간 추출하여 추출물을 제조하였다.Extracts were prepared by adding 60 L of purified water to 1 kg of commercially available herbivorous herbivorous products, 5 kg of Hwanggi, 1 kg of Hwanggi, 2 kg of dwarf, 1.5 kg of dermis and 500 g of licorice, and then extracted with 100 L of distilled water at 100 ° C for 4 hours.
제제예Formulation example
제제예 1: 음료의 제조(단위: 중량%)Formulation Example 1: Preparation of beverage (unit:% by weight)
꿀 5%, 과당 3%, 염산리보플라빈나트륨 0.0001%, 염산피리독신 0.0001%, 및 물 81.9998%와 실시예 1에서 얻어진 조성물 10%를 배합하여 통상의 방법으로 건강 음료를 제조한다.A health drink is prepared by blending 5% of honey, 3% of fructose, 0.0001% of riboflavin sodium chloride, 0.0001% of pyridoxine hydrochloride, and 81.9998% of water and 10% of the composition obtained in Example 1.
제제예Formulation example 2: 로션의 제조(단위: 2: Production of lotion (unit: 중량%weight% ))
실시예 4의 조성물 3.00Composition 3.00 of Example 4
아스코르빈산-2-인산마그네슘염 1.00Ascorbic acid-2-phosphate magnesium salt 1.00
수용성 콜라겐 (1% 수용액) 1.00Water soluble collagen (1% aqueous solution) 1.00
시트르산나트륨 0.10Sodium citrate 0.10
시트르산 0.0[0093] 5Citric acid 0.0 [0093] 5
1,3-부틸렌글리콜 3.001,3-butylene glycol 3.00
정제수 잔량Purified water balance
제제예Formulation example 3: 화장수의 제조(단위: 3: Manufacture of lotion (Unit: 중량%weight% ))
실시예 3의 조성물 2.00Composition 2.00 of Example 3
히드록시에틸렌셀룰로오스(2% 수용액) 12.00Hydroxyethylene Cellulose (2% aqueous solution) 12.00
잔탄검(2% 수용액) 2.00Xanthan gum (2% aqueous solution) 2.00
1,3-부틸렌글리콜 6.001,3-butylene glycol 6.00
글리세린 4.00Glycerin 4.00
히알루론산나트륨(1% 수용액) 5.00Sodium hyaluronate (1% aqueous solution) 5.00
정제수 잔량Purified water balance
시험예Test Example
시험예 1: 아토피 치료 효과 확인Test Example 1: Confirmation of atopy treatment effect
2012년 7월부터 2013년 9월까지 신창한의원 강남점에 내원한 피부질환 환자들 중 아토피 환자 40명을 10명씩 그룹화한 뒤, 각 그룹별로 상기 실시예 1 내지 4의 조성물을 1일 3회 20~70ml씩 총 6개월간 경구 투여한 뒤 증상의 호전 정도를 평가하여 그 결과를 하기 표 1 내지 4에 나타내었다. From July 2012 to September 2013, 40 patients with atopic dermatoses among the patients with skin diseases who visited the Shinchang Korean Oriental Medical Clinic were grouped into 10 groups. The composition of each of the above Examples 1 to 4 was divided into 20 ~ 70 ml each was orally administered for a total of 6 months, and the degree of improvement of symptoms was evaluated. The results are shown in Tables 1 to 4 below.
또한, 본 발명의 조성물의 아토피 치료 효과를 시각적으로 확인할 수 있도록, 각 그룹마다 1명의 아토피 환자에 대하여 호전 정도에 따른 사진을 도 1 내지 4에 나타내었다. 단, 도 1 내지 4에서 (a)는 치료 시작 전의 사진이고, (b)는 각각 실시예 1 내지 4의 조성물을 6개월, 3개월, 8개월 및 4개월 경구 투여한 후의 사진이다.In order to visually confirm the therapeutic effects of the composition of the present invention, photographs according to the degree of improvement for one atopic patient in each group are shown in Figs. 1 to 4. 1 to 4 (a) are photographs before the start of treatment, and (b) are photographs after oral administration of the compositions of Examples 1 to 4 at 6 months, 3 months, 8 months and 4 months, respectively.
상기 표 1 내지 4에서 보는 바와 같이, 본 발명의 조성물의 경구 투여 시 아토피 치료 효과가 뛰어난 것을 볼 수 있으며, 특히 실시예 4의 조성물을 투여한 경우 아토피 치료 활성이 매우 높은 것으로 나타났다. As shown in Tables 1 to 4, the composition of the present invention showed an excellent effect of treating atopic dermatitis when administered orally. In particular, when the composition of Example 4 was administered, the treatment activity of atopic dermatitis was very high.
도 1 내지 4에서 각각의 (a) 및 (b) 사진을 비교해 본 결과, 본 발명의 조성물을 투여함에 따라 성별 및 연령을 불문하고, 다양한 피부 부위에서의 아토피 증상이 매우 호전되고, 뽀얀 피부를 갖게 된 것을 확인할 수 있다.As a result of comparing the photographs (a) and (b) of each of Figs. 1 to 4, it was found that the administration of the composition of the present invention significantly improved atopic symptoms in various skin regions, regardless of sex and age, You can see that you have.
시험예 2: 건선 치료 효과 확인Test Example 2: Confirmation of Psoriasis Treatment Effect
2012년 7월부터 2013년 9월까지 신창한의원 강남점에 내원한 피부질환 환자들 중 건선 피부 질환이라고 진단한 20명을 5명씩 그룹화한 뒤, 각 그룹별로 상기 실시예 2, 4 내지 6의 조성물을 1일 3회 70ml씩 총 6개월간 경구 투여한 뒤 증상의 호전 정도를 평가하여 그 결과를 하기 표 5 내지 8에 나타내었다. From July 2012 to September 2013, 20 patients diagnosed as psoriasis skin disease among the patients with skin diseases who visited the Shinchang Oriental Medical Clinic were grouped into 5 groups, and the compositions of Examples 2, 4 to 6 After oral administration for 70 minutes at a total of 6 months three times a day, the degree of improvement of symptoms was evaluated and the results are shown in Tables 5 to 8 below.
또한, 본 발명의 조성물의 건선 치료 효과를 시각적으로 확인할 수 있도록, 각 그룹마다 1명의 건선 환자에 대하여 호전 정도에 따른 사진을 도 5 내지 8에 나타내었다. 단, 도 5 내지 8에서 (a)는 치료 시작 전의 사진이고, (b)는 각각 실시예 2, 4 내지 6의 조성물을 6개월, 5개월, 6개월 및 4개월 경구 투여한 후의 사진이다. In order to visually confirm the effect of the composition of the present invention on psoriasis, photographs according to the degree of improvement for one psoriasis patient in each group are shown in Figs. 5 to 8. 5 to 8 are photographs before the start of treatment, and (b) are photographs after oral administration of the compositions of Examples 2 and 4 to 6 at 6, 5, 6 and 4 months, respectively.
상기 표 5 내지 8에서 보는 바와 같이, 본 발명의 조성물의 경구 투여 시 건선 치료 효과가 뛰어난 것을 볼 수 있다. As shown in Tables 5 to 8, when the composition of the present invention is orally administered, it has an excellent effect of treating psoriasis.
한편, 도 5 내지 8에 있어서, (a) 및 (b) 각각은 건선 환자에게 실시예 2 및 4 내지 6의 조성물을 투여하기 전과, 일정 기간 경구 투여한 후의 피부 사진을 비교하여 나타낸 것이다.5 to 8, (a) and (b) respectively show skin photographs before and after oral administration of the composition of Examples 2 and 4 to 6 to patients with psoriasis.
도 5 내지 8에서 각각의 (a) 및 (b) 사진을 비교해 본 결과, 본 발명의 조성물을 투여함에 따라 다양한 피부 부위에서의 건선 증상이 매우 호전되어, 건선이 완전히 혹은 거의 대부분이 없어진 것을 확인할 수 있다. As a result of comparing the photographs (a) and (b) of each of FIGS. 5 to 8, it was found that administration of the composition of the present invention significantly improved psoriasis symptoms in various skin areas and completely or almost completely eliminated psoriasis .
시험예 3: 습진 치료 효과 확인Test Example 3: Confirmation of efficacy of eczema treatment
본 발명의 조성물의 습진 치료 효과를 확인하기 위하여, 2012년 7월부터 2013년 9월까지 신창한의원 강남점에 내원한 환자 중 습진 환자 2명에게 실시예 1 및 7의 조성물 각각을 1일 3회 70ml씩 총 8개월 및 9개월 간 경구 투여하였다. In order to confirm the efficacy of the composition of the present invention, two patients with eczema among the patients who visited Gangnam-dong, Shinchang-gu, from July 2012 to September 2013 were administered 70 ml of the compositions of Examples 1 and 7 three times a day Were administered orally for a total of 8 months and 9 months.
본 발명의 조성물의 습진 치료 효과를 시각적으로 확인할 수 있도록, 각 환자들의 치료 시작 전과, 본 발명의 조성물을 일정 기간 경구 투여한 후의 사진을 도 9 내지 10에 (a)와 (b)로 나타내었다. 9 to 10 (a) and (b) are photographs of the composition of the present invention before the start of treatment and after oral administration of the composition of the present invention for a certain period so that the effect of the eczema treatment of the composition of the present invention can be visually confirmed .
도 9 내지 10에서 각각의 (a) 및 (b) 사진을 비교해 본 결과, 본 발명의 조성물을 투여함에 따라 성별 및 연령을 불문하고, 다양한 피부 부위에서의 습진 증상이 습진 부위가 대부분이 없어지고, 일부 부위에서만 습진 증상이 사라진 뒤 거무스름하게 피부 착색이 나타난 것을 볼 수 있다. 다만, 이렇게 착색된 피부도 본 발명의 조성물을 이후 꾸준히 경구 투여하면 색소가 점차 탈락하면서 주변 피부색과 동일하게 정상적으로 변하게 된다.As a result of comparing the photographs (a) and (b) of FIGS. 9 to 10 with each other, it was found that the administration of the composition of the present invention resulted in the disappearance of eczema symptoms in various skin areas regardless of sex and age, , But in some areas, the eczema symptom disappeared, and then the skin coloration appeared to be dark. However, when the composition of the present invention is continuously orally administered, the pigment gradually disappears and normally changes to the surrounding skin color.
시험예 4: 각화증 치료 효과 확인Test Example 4: Confirmation of the effect of keratosis treatment
본 발명의 조성물의 각화증 치료 효과를 확인하기 위하여, 2012년 7월부터 2013년 9월까지 신창한의원 강남점에 내원한 환자 중 각화증 환자 2명 각각에게 실시예 2 및 8의 조성물을 1일 3회 20~70ml씩 총 5개월 및 12개월 간 경구 투여하였다. In order to confirm the therapeutic effect of the composition of the present invention, the compositions of Examples 2 and 8 were administered three times per day to each of two patients with keratosis among patients who visited Kangnam-myeon, Shinchang-ku from July 2012 to September 2013 ~ 70ml in total for 5 months and 12 months.
본 발명의 조성물의 각화증 치료 효과를 시각적으로 확인할 수 있도록, 각 환자들의 치료 시작 전과, 본 발명의 조성물을 일정 기간 경구 투여한 후의 사진을 도 11 내지 12에 (a)와 (b)로 나타내었다. Figs. 11 to 12 show photographs (a) and (b) of the photographs of the patients before the start of treatment and after oral administration of the composition of the present invention for a certain period so that the effect of treating the keratosis of the present invention can be visually confirmed .
도 11 내지 12에서 각각의 (a) 및 (b) 사진을 비교해 본 결과, 본 발명의 조성물을 투여함에 따라, 손바닥에서 각질로 덮혀져 뻣뻣하였던 부위가 부드럽고 매끈해지면서 완치된 것을 확인할 수 있었고, 발바닥 전체에서도 각질이 벗겨지던 증상이 없어지고 전체적으로 매끈한 피부로 회복된 것을 확인할 수 있다. As a result of comparing the photographs (a) and (b) of FIGS. 11 to 12 with each other, it was confirmed that the composition of the present invention was cured by soft, smooth, In the whole soles of the foot, the symptoms that the skin exfoliates disappear, and it is confirmed that the whole skin is restored to smooth skin.
시험예 5: 양진 치료 효과 확인Test Example 5: Confirmation of the effect of the positive treatment
본 발명의 조성물의 양진 치료 효과를 확인하기 위하여, 2012년 7월부터 2013년 9월까지 신창한의원 강남점에 내원한 환자 중 양진 환자 2명 각각에게 실시예 3 및 9의 조성물을 1일 3회 20~70ml씩 총 5개월 및 8주간 경구 투여하였다. In order to confirm the efficacy of the composition of the present invention, the compositions of Examples 3 and 9 were administered three times daily to 20 patients who were admitted to Gangnam Hospital from July 2012 to September 2013 ~ 70ml for a total of 5 months and 8 weeks.
본 발명의 조성물의 양진 치료 효과를 시각적으로 확인할 수 있도록, 각 환자들의 치료 시작 전과, 본 발명의 조성물을 일정 기간 경구 투여한 후의 사진을 도 13 내지 14에 (a)와 (b)로 나타내었다. 13 to 14 (a) and (b) are photographs of each patient before the start of treatment and after oral administration of the composition of the present invention for a certain period in order to visually confirm the effect of the positive treatment of the composition of the present invention .
도 13 내지 14에서 각각의 (a) 및 (b) 사진을 비교해 본 결과, 본 발명의 조성물을 투여함에 따라, 팔과 다리 오금에 넓게 분포하던 양진 증상이 매우 호전된 것을 확인할 수 있다. 다만, 양진은 피부에 시각적으로 드러나는 환부뿐만 아니라, 가려움증이 극심하여 환자들에게 고통을 주는데, 비교적 짧은 기간의 투여로 인해 가려움증 또한 크게 완화되었다. As a result of comparing the photographs (a) and (b) of each of FIGS. 13 to 14, it can be seen that the administration of the composition of the present invention greatly improved the symptoms of widespread distribution in the arms and legs. However, Yangjin is not only a visible part of the skin, but also the itching is very severe, which causes pain to the patients.
시험예 6: 물사마귀 치료 효과 확인Test Example 6: Confirmation of water wart treatment effect
본 발명의 조성물의 물사마귀 치료 효과를 확인하기 위하여, 2012년 7월부터 2013년 9월까지 신창한의원 강남점에 내원한 환자 중 물사마귀 환자 1명에게 실시예 10의 조성물을 1일 3회 30ml씩 총 4주간 경구 투여하였다. In order to confirm the effect of the composition of the present invention on water wart treatment, one of the patients who visited the Shinchang Korean Medical Center from July 2012 to September 2013 was given the composition of Example 10 30 ml Total oral administration for 4 weeks.
본 발명의 조성물의 물사마귀 치료 효과를 시각적으로 확인할 수 있도록, 각 환자들의 치료 시작 전과, 본 발명의 조성물의 경구 투여 후 4주가 경과한 시점에서의 사진을 도 15에 (a)와 (b)로 나타내었다. 15 (a) and 15 (b) are photographs of the warts before treatment and before 4 weeks after oral administration of the composition of the present invention, Respectively.
도 15의 (a) 및 (b) 사진을 비교해 본 결과, 4주 간 본 발명의 조성물을 투여함에 따라, 겨드랑이 부분에 붉은 색으로 자잘하게 존재하던 물사마귀가 완전히 사라진 것을 확인할 수 있다. As a result of comparing the photographs of FIGS. 15 (a) and 15 (b), it can be seen that water warts, which were present in the axilla partly in red color, completely disappeared as the composition of the present invention was administered for 4 weeks.
이상에서 본 발명의 실시예에 대하여 상세하게 설명하였지만, 본 발명의 권리범위는 이에 한정되는 것은 아니고, 특히 도면 사진은 대표적인 치료 예를 보여주는 것으로, 당 기술분야의 통상의 지식을 가진 자라면, 본 발명에서 결명자 및 지구병을 필수 성분으로 포함하는 조성물은 다양한 피부 질환의 개선 및 치료에 우수한 효과를 가짐을 용이하게 알 수 있다. While the embodiments of the present invention have been described in detail, the scope of the present invention is not limited thereto. Particularly, the drawings show typical treatment examples. As a matter of course, It is easy to know that a composition comprising an acaricide and a globe as an essential ingredient in the invention has excellent effects in the improvement and treatment of various skin diseases.
또한, 본 발명은 청구범위에 기재된 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 다양한 수정 및 변형이 가능하다는 것은 당 기술분야의 통상의 지식을 가진 자에게는 자명할 것이다.It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (12)
결명자 추출물 및 지구병 추출물은 건조 중량비로 1:0.5 ~ 5의 비율로 포함되는 것인, 피부 질환의 예방 또는 치료용 약학 조성물.The method according to claim 1,
Wherein said composition comprises at least one selected from the group consisting of a herbal extract and a globe extract in a dry weight ratio of 1: 0.5 to 5.
가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 1종 이상의 약재 추출물을 추가로 포함하는 피부 질환의 예방 또는 치료용 약학 조성물.The method according to claim 1,
A pharmaceutical composition for the prevention or treatment of skin diseases, which further comprises at least one medicinal extract selected from the group consisting of extracts of tea extract, Huanggui extract, Angelica gigantosa extract, Puerariae radix extract, Paeoniae extract, Peony root extract, Dermatophyte extract and Licorice root extract .
추가로 포함되는 각각의 약재 추출물은 건조 중량비로 결명자 추출물 대비 0.2 ~ 5의 비율로 포함되는 피부 질환의 예방 또는 치료용 약학 조성물.The method of claim 3,
Wherein each of the additional pharmacological extracts is contained at a ratio of 0.2 to 5, in terms of the dry weight ratio, to the Cassiae Extract.
상기 피부 질환은 아토피, 건선, 습진, 각화증, 양진 및 물사마귀로 구성되는 군으로부터 선택되는 것인, 피부 질환의 예방 또는 치료용 약학 조성물.5. The method according to any one of claims 1 to 4,
Wherein the skin disease is selected from the group consisting of atopy, psoriasis, eczema, keratosis, ovarian hyperstimulation and water warts.
상기 조성물은 내복용인, 피부 질환의 예방 또는 치료용 약학 조성물.5. The method according to any one of claims 1 to 4,
Wherein said composition is for underwear.
결명자 추출물 및 지구병 추출물은 건조 중량비로 1: 0.5 ~ 5의 비율로 포함되는 것인, 피부 질환 개선용 식품 조성물.8. The method of claim 7,
Wherein the composition comprises 1: 0.5 ~ 5 in terms of a dry weight ratio.
가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 1종 이상의 약재 추출물을 추가로 포함하는 피부 질환 개선용 식품 조성물.8. The method of claim 7,
A composition for improving skin diseases, which further comprises at least one herbal extract selected from the group consisting of extracts of tea extract, Huanggui extract, Angelica keiskei extract, Puerariae radix extract, Paeoniae extract, Peony root extract, Dermatophyte extract and Licorice root extract.
결명자 추출물 및 지구병 추출물은 건조 중량비로 1: 0.5 ~ 5의 비율로 포함되는 것인, 피부 질환 개선용 화장료 조성물.11. The method of claim 10,
Wherein said composition comprises at least one selected from the group consisting of a herbaceous perennial herb extract and a globular herb extract at a dry weight ratio of 1: 0.5 to 5.
가구자 추출물, 황기 추출물, 당귀 추출물, 갈근 추출물, 백출 추출물, 작약 추출물, 진피 추출물 및 감초 추출물로 구성되는 군으로부터 선택되는 1종 이상의 약재 추출물을 추가로 포함하는 피부 질환 개선용 화장료 조성물.
11. The method of claim 10,
A cosmetic composition for the improvement of skin diseases, which further comprises at least one herbal extract selected from the group consisting of a herbal extract, a herbal extract, a Angelica keiskei extract, a Puerariae Radix extract, a Paeonia extract, a Peony root extract, a Dermatophyte extract and a licorice extract.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2014/004780 WO2015182799A1 (en) | 2014-05-27 | 2014-05-27 | Composition for improving skin diseases comprising hovenia dulcis and semen allii tuberosi |
KRPCT/KR2014/004780 | 2014-05-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150023539A Division KR101622104B1 (en) | 2014-05-27 | 2015-02-16 | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING SKIN DISEASE, COMPRISING EXTRACT OF Cassia obtussifolia L. AND EXTRACT OF Hovenia ducis |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20160056866A true KR20160056866A (en) | 2016-05-20 |
Family
ID=54699115
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150023539A KR101622104B1 (en) | 2014-05-27 | 2015-02-16 | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING SKIN DISEASE, COMPRISING EXTRACT OF Cassia obtussifolia L. AND EXTRACT OF Hovenia ducis |
KR1020160057079A KR20160056866A (en) | 2014-05-27 | 2016-05-10 | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING SKIN DISEASE, COMPRISING EXTRACT OF Cassia obtussifolia L. AND EXTRACT OF Hovenia ducis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150023539A KR101622104B1 (en) | 2014-05-27 | 2015-02-16 | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING SKIN DISEASE, COMPRISING EXTRACT OF Cassia obtussifolia L. AND EXTRACT OF Hovenia ducis |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR101622104B1 (en) |
WO (1) | WO2015182799A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102368238B1 (en) | 2017-03-16 | 2022-03-02 | 주식회사 차메디텍 | Cosmetic composition for improving acne comprising cassia obtusifolia seed extract and pueraria lobata symbiosome extract and manufacturing method thereof |
CN108524834A (en) * | 2018-06-11 | 2018-09-14 | 张斌 | A kind of skin antipruritic liquid and its application method |
CN109602677B (en) * | 2019-01-24 | 2021-12-07 | 桂林理工大学 | Traditional Chinese medicine moisturizing cream and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100881445B1 (en) * | 2002-07-19 | 2009-02-03 | (주) 김형민한약연구소 | Composition for protection of skin and improvement of skin diseases and process for preparation thereof |
KR100536744B1 (en) * | 2003-08-14 | 2005-12-14 | 주식회사 바이오랜드 | Cosmetic composition including an extract from Hovenia Dulcis Fruit having skin age resisting effect and the preparation the same |
JP2008074802A (en) * | 2006-09-25 | 2008-04-03 | Oriza Yuka Kk | Skin-beautifying composition |
KR100844516B1 (en) * | 2007-02-12 | 2008-07-08 | 주식회사 사임당화장품 | Cosmetic composition containing astragalus root extract |
KR101111712B1 (en) * | 2009-04-22 | 2012-02-10 | 김병구 | Manufacturing methods of using herbs medicine for skin |
KR101408405B1 (en) * | 2012-11-19 | 2014-06-17 | 윤종성 | COMPOSITION FOR IMPROVING SKIN DISEASE, COMPRISING Hovenia ducis AND SEED OF Allium tuberosum |
-
2014
- 2014-05-27 WO PCT/KR2014/004780 patent/WO2015182799A1/en active Application Filing
-
2015
- 2015-02-16 KR KR1020150023539A patent/KR101622104B1/en active IP Right Grant
-
2016
- 2016-05-10 KR KR1020160057079A patent/KR20160056866A/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR101622104B1 (en) | 2016-05-18 |
KR20150136569A (en) | 2015-12-07 |
WO2015182799A1 (en) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104840722A (en) | Functional health-preserving treasure composition as well as preparation method and application method thereof | |
CN104940606A (en) | Deer-horn gelatin health product for conditioning eight types of abnormal body constitution | |
CN104825970A (en) | Health care product containing Noni juice | |
CN101954017B (en) | Balneotherapy effervescent tablets for moisturizing and whitening skin | |
CN103555530A (en) | Lily healthcare medicinal liquor | |
CN103720903A (en) | Anti-inflammation lung-clearing and liver-protecting tea and preparation method thereof | |
CN102640821B (en) | Solid instant health care tea and preparation method of solid instant health care tea | |
CN102363011B (en) | Chinese medicinal composition for dispel effects of alcohol, and preparation method thereof | |
KR101622104B1 (en) | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING SKIN DISEASE, COMPRISING EXTRACT OF Cassia obtussifolia L. AND EXTRACT OF Hovenia ducis | |
CN102512644B (en) | Traditional Chinese medicine composition for removing freckles and nourishing skin and preparation method for same | |
CN104225417A (en) | Traditional Chinese medicine composition with function of assisting improvement of memory and preparation method thereof | |
KR102192573B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
CN109077321A (en) | A kind of composition and preparation method thereof with strengthen immunity and antioxidation | |
CN108785594A (en) | A kind of Chinese herbal ointment formula and preparation method for intervening phlegm-dampness constitution | |
KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
CN103751762B (en) | A kind ofly skin cell is promoted to recombinate and can the product of slow down aging | |
KR101408405B1 (en) | COMPOSITION FOR IMPROVING SKIN DISEASE, COMPRISING Hovenia ducis AND SEED OF Allium tuberosum | |
CN105194487A (en) | Whitening and beautifying traditional Chinese medicine composition and facial mask and preparation method | |
CN102652808B (en) | Menstruation regulating and beautifying capsule | |
KR20110075584A (en) | Composition for improving atopic dermatitis | |
KR101783549B1 (en) | Health supplement food containing dha for recovering fatigue, and method of manufacturing the same | |
CN104147186A (en) | Rose essential oil hydrogel plaster and preparation method thereof | |
KR20060030575A (en) | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism | |
CN107951951B (en) | Traditional Chinese medicine composition for removing senile plaques and preparation method thereof | |
KR102375209B1 (en) | Composition comprising collagen peptides and herbal extracts for improving muscle sedation, convulsion and pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent |